(Credit: Celltrion Healthcare) The launch comes nearly four months after the drug received marketing authorization from the FDA on October 20. Johnson & Johnson, the creator of the original infliximab, Remicade, faced challenges in converting intravenous infliximab to a subcutaneous injection. To ensu...
Celltrion has unveiled a partnership with Express Scripts, one of the top three pharmacy benefit managers (PBMs) in the U.S., for its subcutaneous (SC) Remicade biosimilar, Zymfentra, on Monday. Celltrion announced the inclusion of its subcutaneous (SC) Remicade biosimilar, Zymfentra, in Expr...